328 related articles for article (PubMed ID: 10706380)
1. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models.
Tokioka T; Shibasaki M; Fujimori A; Matsuda-Satoh Y; Uchida W; Inagaki O; Yanagisawa I
Biol Pharm Bull; 2000 Feb; 23(2):174-81. PubMed ID: 10706380
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload.
Tokioka-Akagi T; Fujimori A; Shibasaki M; Inagaki O; Yanagisawa I
Jpn J Pharmacol; 2001 May; 86(1):79-85. PubMed ID: 11430476
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs.
Shibasaki M; Fujimori A; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):175-84. PubMed ID: 9369371
[TBL] [Abstract][Full Text] [Related]
6. Increased vascular formation of angiotensin II in one-kidney, one clip hypertension.
Leite R; Salgado MC
Hypertension; 1992 Jun; 19(6 Pt 1):575-81. PubMed ID: 1317351
[TBL] [Abstract][Full Text] [Related]
7. Enalapril prevents aortic hyperreactivity and remodelling in one-kidney, one-clip hypertensive rats without reducing arterial pressure.
Cunha V; Salgado HC; Salgado MC
Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):474-9. PubMed ID: 10874501
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats.
Yamaguchi N; Fujimoto K; Fujii T; Suzuki T; Kawashima K
Jpn J Pharmacol; 1997 Jan; 73(1):83-91. PubMed ID: 9032137
[TBL] [Abstract][Full Text] [Related]
9. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
Cockcroft JR; Sciberras DG; Goldberg MR; Ritter JM
J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360
[TBL] [Abstract][Full Text] [Related]
10. Role of angiotensin-(1-7) in the modulation of the baroreflex in renovascular hypertensive rats.
Britto RR; Santos RA; Fagundes-Moura CR; Khosla MC; Campagnole-Santos MJ
Hypertension; 1997 Sep; 30(3 Pt 2):549-56. PubMed ID: 9322980
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
[TBL] [Abstract][Full Text] [Related]
12. Enhanced slow pressor effect of angiotensin II in two-kidney, one clip rats.
Melaragno MG; Fink GD
Hypertension; 1995 Feb; 25(2):288-93. PubMed ID: 7843781
[TBL] [Abstract][Full Text] [Related]
13. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
[TBL] [Abstract][Full Text] [Related]
14. Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats.
Okamura T; Miyazaki M; Inagami T; Toda N
Hypertension; 1986 Jul; 8(7):560-5. PubMed ID: 3013774
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme.
Becari C; Teixeira FR; Oliveira EB; Salgado MC
Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H565-70. PubMed ID: 21602471
[TBL] [Abstract][Full Text] [Related]
16. Intrarenal angiotensin converting enzyme inhibition in spontaneously hypertensive rats.
Aihara H; Ogawa H; Kasuya A; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S
Eur J Pharmacol; 1999 May; 373(1):35-40. PubMed ID: 10408249
[TBL] [Abstract][Full Text] [Related]
17. Exercise training attenuates angiotensin II-induced vasoconstriction in the aorta of normotensive but not hypertensive rats.
Oliveira PR; Oliveira PB; Rossignoli PS; Spadella MA; Chies AB
Exp Physiol; 2020 Apr; 105(4):732-742. PubMed ID: 31999028
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
20. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
